Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,544Revenue (TTM) $M1.3Net Margin (%)-19,432.9Altman Z-Score7.9
Enterprise Value $M1,167EPS (TTM) $-5.3Operating Margin %-19,376.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score36.7Pre-tax Margin (%)-19,432.9Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %2.4Quick Ratio6.7Cash flow > EarningsY
Price/Sales9435-y EBITDA Growth Rate %36.1Current Ratio6.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-89.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-123.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M54.6ROIC % (ttm)-813.7Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

SRPT is held by these investors:

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mahatme SandeshSenior Vice President, CFO 2016-10-17Sell30,000$50.08-43.53view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-22Sell40,179$60-52.87view
Howton David TSVP, General Counsel 2016-09-22Sell7,000$60-52.87view
Ruff ShamimSVP, Regulatory Affairs & Qual 2016-09-22Sell7,311$60-52.87view
Aphale JayantVP, Technical Operations 2016-09-19Sell35,000$50-43.44view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-19Sell24,352$50-43.44view
Howton David TSVP, General Counsel 2016-09-19Sell9,304$50-43.44view
Kaye Edward M. MDSVP Interim CEO & CMO 2016-09-14Sell24,557$30-5.73view
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.2873.71view
Barry RichardDirector 2016-03-14Buy75,000$15.6680.59view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Santhera opens Mass. office as local Duchenne ecosystem grows Feb 17 2017
Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl Feb 16 2017
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent... Feb 15 2017
Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal Feb 14 2017
Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000... Feb 13 2017
Sarepta Muscular Dystrophy Drug Faces Competition Feb 10 2017
FDA approves Marathon Pharma's Duchenne muscular dystrophy drug Feb 09 2017
Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment Feb 09 2017
Catabasis Hits 52-Week Low on Poor DMD Drug Study Data Feb 02 2017
Sarepta: It's Not Whether Insurers Will Pay. It's How Much They'll Pay Feb 01 2017
Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results Feb 01 2017
Catabasis shares plummet on Duchenne trial failure Jan 31 2017
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 31 2017
Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US :... Jan 23 2017
Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug Jan 19 2017
Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential Jan 19 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)